Alto Neuroscience (NYSE:ANRO) Posts Earnings Results, Beats Expectations By $0.05 EPS

Alto Neuroscience (NYSE:ANRO) announced its earnings results on Tuesday. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.05, Zacks reports.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO traded up $0.08 during midday trading on Thursday, hitting $4.61. The company had a trading volume of 529,519 shares, compared to its average volume of 375,478. Alto Neuroscience has a twelve month low of $3.61 and a twelve month high of $24.00. The business has a 50-day simple moving average of $10.02 and a two-hundred day simple moving average of $11.46. The company has a quick ratio of 19.85, a current ratio of 19.85 and a debt-to-equity ratio of 0.04.

Wall Street Analyst Weigh In

Several analysts have commented on the company. RODMAN&RENSHAW cut Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Stifel Nicolaus lowered their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alto Neuroscience has an average rating of “Moderate Buy” and an average target price of $20.00.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.